2,3-二羟基苯甲酸乙酯 | 3943-73-5

• 物质功能分类: 生物 - 细胞培养 - 添加剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二羟基苯甲酸乙酯
• 英文名称: ethyl 2,3-dihydroxybenzoate
• 英文别名: 2,3-Dihydroxybenzoesaeureethylester
• CAS: 3943-73-5
• 化学式: C₉H₁₀O₄
• 分子量: 182.176
• InChiKey: RHMQSXRCGOZYND-UHFFFAOYSA-N

物化性质

• 熔点：
  65-67°C

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2918290000
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温和干燥环境下使用。

SDS

Name:	2 3-Dihydroxy-benzoic acid ethyl ester 97% Material Safety Data Sheet
Synonym:	Ethyl 2,3-dihydroxybenzoat
CAS:	3943-73-5

Section 1 - Chemical Product MSDS Name:2 3-Dihydroxy-benzoic acid ethyl ester 97% Material Safety Data Sheet
Synonym:Ethyl 2,3-dihydroxybenzoat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
3943-73-5	2,3-Dihydroxy-benzoic acid ethyl ester	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 3943-73-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 65 - 67 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H10O4
Molecular Weight: 182.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 3943-73-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3-Dihydroxy-benzoic acid ethyl ester - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 3943-73-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 3943-73-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 3943-73-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二羟基苯甲酸乙酯 在 lithium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以71%的产率得到苯甲酸,二羟基-
  参考文献：
  名称：

  D-葡萄糖的儿茶酸和2,4,5-三羟基苯甲酸乙酯。

  摘要：

  描述了由D-葡萄糖衍生的β-酮酸酯合成儿茶酸（1）和2,4,5-三羟基苯甲酸乙酯（2）。将糖β-酮酸酯3的水解得到的多羟基β-酮酸酯进行醛醇缩合，得到4，烯醇化，脱水和氢化后得到2,4,5-三羟基苯甲酸乙酯（2）。另一方面，醛醇缩合产物4的加氢得到多羟基化的酮尿嘧啶糖6，经过温和的酸处理和酯在碱性介质中的水解，生成儿茶酸1。中间体4与3-脱氢hydro草酸（一种来自D-葡萄糖在原儿茶酸的合成中。

  DOI：

  10.1016/j.carres.2009.02.002
• 作为产物：
  描述：

  苯甲酸,二羟基- 在 氯化亚砜 、 三乙胺 作用下， 以 氯仿 为溶剂， 反应 18.0h， 生成 2,3-二羟基苯甲酸乙酯
  参考文献：
  名称：

  追逐弱力：分层组装螺旋作为弱相互作用能量学评估的探针

  摘要：

  伦敦色散力是分子间最弱的相互作用。因此，它们对化学过程的影响通常很小，但绝对不能忽视，甚至在接触面大的分子的情况下变得很重要。分层组装的双核钛 (IV) 螺旋是一个罕见的例子，其中即使存在强内聚溶剂效应，也可以在溶液中直接观察伦敦色散力。因此，分散力不会无限制地支持二聚复合物的形成。尽管它们对单体复合单元的二聚化具有一些有利的焓贡献，但大的柔性取代基在构象上受到相互作用的限制，从而导致熵劣势。二聚螺旋体是熵不稳定的。

  DOI：

  10.1021/jacs.7b10098

文献信息

• Conversion of Simple Cyclohexanones into Catechols
  作者：Yu-Feng Liang、Xinyao Li、Xiaoyang Wang、Miancheng Zou、Conghui Tang、Yujie Liang、Song Song、Ning Jiao

  DOI：10.1021/jacs.6b07269

  日期：2016.9.21

  A novel I2-catalyzed direct conversion of cyclohexanones to substituted catechols under mild and simple conditions has been described. This novel transformation is remarkable with the multiple oxygenation and dehydrogenative aromatization processes enabled just by using DMSO as the solvent, oxidant, and oxygen source. This metal-free and simple system demonstrates a versatile protocol for the synthesis

  描述了在温和和简单的条件下，一种新型的 I2 催化的环己酮直接转化为取代的儿茶酚。仅使用 DMSO 作为溶剂、氧化剂和氧源即可实现多重氧化和脱氢芳构化过程，这种新颖的转变是显着的。这种不含金属的简单系统展示了一种合成高价值取代儿茶酚的通用方案，因此简化了用于药物发现的生物重要分子的合成和修饰。
• 具麻醉作用的羟基苯甲酸酯镁盐及制备方法
  申请人：杭州奥默医药股份有限公司

  公开号：CN104513166B

  公开（公告）日：2016-03-30

  本发明提供一种具有麻醉作用的羟基苯甲酸酯镁盐，通过在室温下将化合物（II）和蒸馏水混合，搅拌下加入氢氧化镁的水溶液，过滤，冷冻干燥得到目的化合物（I）。本发明的制备方法条件温和，操作简单，具有工业化前景。本发明所述的化合物由于水溶性良好，制成注射剂时可不加入表面活性剂等存在安全性不足的辅料，同时也可减少或去除注射痛，增加患者依从性；麻醉起效快、苏醒恢复快，临床使用安全，应用价值大。本发明化合物结构式如下：。
• SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
  申请人：Kuo Sheng-Chu

  公开号：US20120015908A1

  公开（公告）日：2012-01-19

  A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), P(═O)(OM) 2 , P═O(O 2 M), S(═O)(OH) 2 , S(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , S(═O)(OH)(OM), S(═O)(OM) 2 ; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C 6 -C 20 )aryl, (C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkyl(C 6 -C 20 )aryl, (C 1 -C 18 )alkyl(C 6 -C 20 )heteroaryl, hydroxy(C 6 -C 20 )aryl, hydroxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )heteroaryl, halo(C 6 -C 20 )aryl, halo(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )aryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )heteroaryl, (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )aryl, or (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )heteroaryl, and their OR 8 substutes; R 5 is (C 1 -C 18 alkoxy, hydrogen, hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR 8 , or R 5 and R 6 are (C 1 -C 18 )dioxy provided that R 7 is hydrogen; R 6 is hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR R , (C 1 -C 18 )alkoxy, (C 1 -C 18 )alkylamino, or (C 1 -C 18 )cycloalkylamino, or R 6 and R 7 are (C 1 -C 18 )dioxy provided that R 5 is hydrogen; R 7 is hydrogen, halo or OR 8 , hydroxyl, or O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl; and R 8 is P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkyl(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), or P(═O)(OM) 2 , P═O(O 2 M).

  根据以下公式披露了一种化合物：或其药学上可接受的盐、前药、溶剂合物或代谢物，其中R为氢、P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、P(═O)(OM)2、P═O(O2M)、S(═O)(OH)2、S(═O)(O(C1-C18)烷基(C6-C20)芳基)2、S(═O)(OH)(OM)、S(═O)(OM)2；M为一价或二价金属离子，或烷基铵离子；W为(C6-C20)芳基、(C6-C20)杂芳基、(C1-C18)烷基(C6-C20)芳基、(C1-C18)烷基(C6-C20)杂芳基、羟基(C6-C20)芳基、羟基(C6-C20)杂芳基、(C1-C18)烷氧基(C6-C20)芳基、(C1-C18)烷氧基(C6-C20)杂芳基、(C1-C18)烷二氧基(C6-C20)芳基、(C1-C18)烷二氧基(C6-C20)杂芳基、卤代(C6-C20)芳基、卤代(C6-C20)杂芳基、(C1-C18)烷基氨基(C6-C20)芳基、(C1-C18)烷基氨基(C6-C20)杂芳基、(C1-C18)环烷基氨基(C6-C20)芳基，或(C1-C18)环烷基氨基(C6-C20)杂芳基，以及它们的OR8取代基；R5为(C1-C18)烷氧基、氢、羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或OR8，或R5和R6为(C1-C18)二氧基，前提是R7为氢；R6为羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或ORR、(C1-C18)烷氧基、(C1-C18)烷基氨基，或(C1-C18)环烷基氨基，或R6和R7为(C1-C18)二氧基，前提是R5为氢；R7为氢、卤素或OR8、羟基，或O—(C1-C18)烷基(C6-C20)芳基；R8为P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、或P(═O)(OM)2、P═O(O2M)。
• Structure-Activity Relationships of Neuritogenic Gentiside Derivatives
  作者：Yan Luo、Kaiyue Sun、Lin Li、Lijuan Gao、Guangfa Wang、Yuan Qu、Lan Xiang、Ling Chen、Yongzhou Hu、Jianhua Qi

  DOI：10.1002/cmdc.201100348

  日期：2011.11.4

  Relationship advice: Studying the structure–activity relationships of gentisides revealed that the length of the alkyl chain, number and position of hydroxy groups on the benzene ring, and the type of linker between the benzene ring and alkyl chain have significant effects on their neuritogenic activities. Tetradecyl 2,3‐dihydroxybenzoate (ABG‐001) was the most promising lead compound, inducing significant

  关系建议：研究龙胆苷的结构-活性关系发现，烷基链的长度，苯环上羟基的数量和位置以及苯环和烷基链之间的连接基类型对它们的神经生成活性有重要影响。2,3-二羟基苯甲酸十四烷基酯（ABG-001）是最有前途的先导化合物，可通过激活ERK信号传导途径诱导明显的神经突长出。
• Novel heteroaryl derivatives, their preparation and use
  申请人：H. Lundbeck A/S

  公开号：US20030050306A1

  公开（公告）日：2003-03-13

  A heteroaryl derivative having the formula (I) 1 any of its enantiomers or any mixture thereof, wherein X is —O—, —S—, or CR 4 R 5 —; and Y is —CR 6 R 7 ; —CR 6 R 7 —CR 8 R 9 —, or —CR 6 —CR 7 ; or X and Y together form a group —CR 4 ═R 5 —, or —CR 4 ═CR 5 —CR 6 R 7 —; Z is —O—, or —S—; W is N, C, or CH; n is 2, 3, 4, 5, 6, 7, 8, 9 or 10; m is 2 or 3; A is O or S wherein the doted lines mean an optional bond. The compounds of the invention are considered useful for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and neurological disorders such as psychosis.

  具有以下结构式(I)的杂环芳基衍生物，其中X为—O—、—S—或CR4R5—；Y为—CR6R7、—CR6R7—CR8R9—或—CR6—CR7；或者X和Y一起形成一个基团—CR4═R5—或—CR4═CR5—CR6R7—；Z为—O—或—S—；W为N、C或CH；n为2、3、4、5、6、7、8、9或10；m为2或3；A为O或S，其中点线表示可选键。该发明的化合物被认为对治疗情感障碍，如广泛性焦虑障碍、恐慌障碍、强迫症、抑郁症、社交恐惧症和进食障碍，以及神经症如精神病等是有用的。